Narin AKICI, Volkan AYDIN, Ahmet AKICI, N. İpek KIRMIZI, Mesil AKSOY, Banu BAYAR

Off-label drug use in pediatric patients: a comparative analysis with nationwide routine prescription data

Background. Children constitute a special population for off-label drug use (OLDU), yet limited drug-focused data exist regarding pediatric OLDU in clinical practice. This study aimed to investigate pediatric OLDU practice and compare it with pediatric drug utilization patterns of routine prescribing data. Methods. This cross-sectional study examined all approved pediatric OLDU applications, compared with electronic prescription data on national Prescription Information System of Turkish Medicines and Medical Devices Agency in 2015. OLDU applications and prescriptions were analyzed for demographic characteristics, healthcare/socioeconomic indices as well as details of drugs and diagnoses. Results. We found 7,896 OLDU applications and 7,029,512 prescriptions for the pediatric population in 2015. OLDU applications and prescriptions were mostly practiced for “2-11-year-old” children (52.7% vs. 63.4%, respectively; p

PDF

___

1. Woodcock J, Woosley R. The FDA critical path initiative and its influence on new drug development. Annu Rev Med 2008; 59: 1-12.
2. Budetti PP. Ensuring safe and effective medications for children. JAMA 2003; 290: 950-951.
3. Cerreta F, Eichler HG, Rasi G. Drug policy for an aging population-the European Medicines Agency’s geriatric medicines strategy. N Engl J Med 2012; 367: 1972-1974.
4. T.C. Sağlık Bakanlığı Türkiye İlaç Tıbbi Cihaz Kurumu. Endikasyon Dışı İlaç Kullanım Kılavuzu, 09.02.2019. Available at: www.titck.gov.tr/storage/ Archive/2019/legislation/601621f0-2e3e-40d4-97cd65bef02b1a61.pdf (Date of access: 5th November 2020)
5. Frattarelli DA, Galinkin JL, Green TP, et al; American Academy of Pediatrics Committee on Drugs. Offlabel use of drugs in children. Pediatrics 2014; 133: 563-567.
6. Poole SG, Dooley MJ. Off-label prescribing in oncology. Support Care Cancer 2004; 12: 302-305.
7. Rayburn WF, Farmer KC. Off-label prescribing during pregnancy. Obstet Gynecol Clin North Am 1997; 24: 471478.
8. Mühlbauer B, Janhsen K, Pichler J, Schoettler P. Offlabel use of prescription drugs in childhood and adolescence an analysis of prescription patterns in Germany. Dtsch Arztebl Int 2009; 106: 25-31.
9. Olsson J, Kimland E, Pettersson S, Odlind V. Pediatric drug use with focus on off-label prescriptions in Swedish outpatient care - a nationwide study. Acta Paediatr 2011; 100: 1272-1275.
10. Cuzzolin L, Zaccaron A, Fanos V. Unlicensed and off-label uses of drugs in pediatricpediatrics : a review of the literature. Fundam Clin Pharmacol 2003; 17: 125-131.
11. World Health Organization. Promoting safety of medicines for children. World Health Organization, 2007.
12. Kimland E, Odlind V. Off-label drug use in pediatric patients. Clinical Pharmacol Ther2012; 91: 796-801.
13. de Souza AS Jr, Dos Santos DB, Rey LC, Medeiros MG, Vieira MG, Coelho HLL. Off-label use and harmful potential of drugs in a NICU in Brazil: a descriptive study. BMC Pediatr 2016; 16: 13.
14. Moulis F, Durrieu G, Lapeyre-Mestre M. Off-label and unlicensed drug use in children population. Therapie 2018; 73: 135-149.
15. Oguz SS, Kanmaz HG, Dilmen U. Off-label and unlicensed drug use in neonatal intensive care units in Turkey: the old-inn study. Int J Clin Pharm 2012; 34: 136-141.
16. Aksoy M, Alkan A, Isli F. Rational drug use promotional activities of Ministry of Health. Türkiye Klin J Pharmacol-Special Top 2015; 3: 19-26.
17. Turkish Statistical Institute. Turkish Statistical System and Turkstat Istanbul Regional Office. Study Visit of the UNSD, ESCAP and OSCE to Turkey, 17 Sep 2015, İstanbul. Available at: https://unstats.un.org/unsd/ demographic/meetings/wshops/Turkey/2015/docs/ Presentations/Session15-Turkstat_overview_ENG. pdf (Date of access: 28th August 2020).
18. The Ministry of Health of Turkey. Turkey Health Statistics Yearbook 2015. Ankara, 2016.
19. T.C. Kalkınma Bakanlığı. İllerin ve Bölgelerin Sosyo-Ekonomik Gelişmişlik Sıralaması Araştırması (SEGE-2011) [Ministry of Development (Turkey), Survey of Socio-Economic Development Ranking of Provinces and Regions], Ankara, 2013.
20. Ministry of Interior. Number of People by Age in General Directorate of Civil Registration and Citizenship, 2018.
21. Nir-Neuman H, Abu-Kishk I, Toledano M, Heyman E, Ziv-Baran T, Berkovitch M. Unlicensed and offlabel medication use in pediatric and neonatal intensive care units: no change over a decade. Adv Ther 2018; 35: 1122-1132.
22. Dagnew AB, Tewabe T, Murugan R. Level of modern health care seeking behaviors among mothers having under five children in Dangila town, north West Ethiopia, 2016: a cross sectional study. Ital J Pediatr 2018; 44: 44-61.
23. Sahin A, Akici A, Aydin V, Melik B, Aksoy M, Alkan A. Variation of antibiotic consumption and its correlated factors in Turkey. Eur J Clin Pharmacol 2017; 73: 867-873.
24. Bayram D, Kırmızı NI, Özdamar EN, Bayar B, Gürsöz H, Akıcı A. Investigation of the off-label drug use at provincial and regional levels. Gazi Med J 2018; 29: 312-318.
25. Masiero G, Filippini M, Ferech M, Goossens H. Socioeconomic determinants of outpatient antibiotic use in Europe. Int J Public Health 2010; 55: 469-478.
26. Özdamar EN, Akici A, Alkan A, Bayar B, Gürsöz H. A nationwide evaluation of off-label drug utilization in Turkey. Turkish J Med Sci 2017; 47: 1229-1238.
27. Stachnik J, Gabay M. Biologics in Pediatrics. In: Field MJ, Boat TT (eds). Safe and Effective Medicines for Children: Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act. Washington (DC): National Academies Press (US), 2012.
28. Yazılıtaş F, Aydoğ Ö, Özlü SG, et al. Canakinumab treatment in children with familial Mediterranean fever: report from a single center. Rheumatol Int 2018; 38: 879-885.
29. Sturkenboom MCJM, Verhamme KMC, Nicolosi A, et al; TEDDY European Network of Excellence. Drug use in children: cohort study in three European countries. BMJ 2008; 337: a2245.
30. Thrane N, Sørensen HT. A one-year populationbased study of drug prescriptions for Danish children. Acta Paediatr 1999; 88: 1131-1136.
31. Lindell-Osuagwu L, Hakkarainen M, Sepponen K, Vainio K, Naaranlahti T, Kokki H. Prescribing for off-label use and unauthorized medicines in three pediatric wards in Finland, the status before and after the European Union Pediatric Regulation. J Clin Pharm Ther 2014; 39: 144-153.
32. Palmaro A, Bissuel R, Renaud N, et al. Off-label prescribing in pediatric outpatients. Pediatrics 2015; 135: 49-58.
33. Walsh PR, Johnson S. Treatment and management of children with haemolytic uraemic syndrome. Arch Dis Child 2018; 103: 285-291.
34. Loirat C, Fakhouri F, Ariceta G, et al; HUS International. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2016; 31: 15- 39.
35. Castañeda-Sanabria J, Hajage D, Le Jouan M, Perozziello A, Tubach F. Off-label use of the expensive orphan drug eculizumab in France 2009- 2013 and the impact of literature: focus on the transplantation field. Eur J Clin Pharmacol 2016; 72: 737-746.
36. Turkish Medicines and Medical Devices Agency. Soliris (eculizumab) Summary of Product Characteristics. Available at: www.titck.gov.tr/ storage/Archive/2020/kubKtAttachments/SOLIRIS 300mg30mlkonsantreinfzyonzeltisikbtemiz_6e258c 8f-5ecd-4743-8d4c-64fc86a06331.pdf (Date of access: 5th November 2020)
37. FDA. Cellcept (mycophenolate mofetil) Prescribing Information. 2019. Available at: www.accessdata. fda.gov/ drugsatfda_docs/ label/2019/050722s040, 050723s041, 050758s037, 050759s045lbl.pdf (Date of access: 5th November 2020)
38. Turkish Medicines and Medical Devices Agency. Cellcept (Mycophenolate mofetil) Summary of Product Characteristics. 2019. Available at: www.titck. gov.tr/storage/Archive/2020/kubKtAttachments/ TTCKCELLCEPT250MGKAPSLUYGUNKB_ bf50215d-3fbf-427b-bc7c-37427a9ff328.pdf (Date of access: 5th November 2020)
39. Downing HJ, Pirmohamed M, Beresford MW, Smyth RL. Pediatric use of mycophenolate mofetil. Br J Clin Pharmacol 2013; 75: 45-59.
40. Moudgil A, Bagga A, Jordan SC. Mycophenolate mofetil therapy in frequently relapsing steroiddependent and steroid-resistant nephrotic syndrome of childhood: current status and future directions. Pediatr Nephrol 2005; 20: 376-1381.
41. Chen Y, Li YM, Yang SL, Li Y, Liang M. Efficacy and safety of mycophenolate mofetil treatment in IgA nephropathy: a systematic review. BMC Nephrol 2014; 15: 193.
42. Zhao Z, Liao G, Li Y, Zhou S, Zou H. The efficacy and safety of rituximab in treating childhood refractory nephrotic syndrome: a meta-analysis. Sci Rep 2015; 5: 8219.
43. Ramos-Casals M, García-Hernandez FJ, de Ramón E, et al; BIOGEAS Study Group. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 2010; 28: 468-476.
44. King C, Logan S, Smith SW, Hewins P. The efficacy of rituximab in adult frequently relapsing minimal change disease. Clin Kidney J 2017; 10: 16-19.
45. Fenoglio R, Sciascia S, Beltrame G, et al. Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome. Oncotarget 2018; 9: 28799-28804.
46. FDA. Vimpat (Lacosamide) Summary of Product Characteristics, 2017. Available at: www.accessdata.fda.gov/drugsatfda_docs/ label/2017/022253s039,022254s030,022255s022lbl.pdf (Date of access: 5th November 2020)
47. Turkish Medicines and Medical Devices Agency. Benvida (Lacosamide) Summary of Product Characteristics. Available at: www.titck.gov. tr/storage/Archive/2019/kubKtAttachments/ yay%C4%B1nlanacak-k%C3%BCb-benvida%20 10%20%C4%B1v%20%C3%A7%C3%B6z. pdf_6596367d-270f-46da-875a-1946e652d1fe.pdf (Date of access: 5th November 2020)
48. Dang LT, Silverstein FS. Drug treatment of seizures and epilepsy in newborns and children. Pediatr Clin North Am 2017; 64: 1291-1308.
49. Grosso S, Parisi P, Spalice A, Verrotti A, Balestri P. Efficacy and safety of lacosamide in infants and young children with refractory focal epilepsy. Eur J Paediatr Neurol 2014; 18: 55-59.
50. Ackers R, Murray ML, Besag FMC, Wong ICK. Prioritizing children’s medicines for research: a pharmaco-epidemiological study of antiepileptic drugs. Br J Clin Pharmacol 2007; 63: 689-697.
51. Dörks M, Langner I, Timmer A, Garbe E. Treatment of pediatric epilepsy in Germany: antiepileptic drug utilisation in children and adolescents with a focus on new antiepileptic drugs. Epilepsy Res 2013; 103: 45-53.
52. Abman SH, Hansmann G, Archer SL, et al; American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Surgery and Anesthesia; and the American Thoracic Society. Pediatric pulmonary hypertension. Guidelines From the American Heart Association and American Thoracic Society. 2015; 132: 2037-2099.
53. Ivy D. Advances in pediatric pulmonary arterial hypertension. Curr Opin Cardiol 2012; 27: 70-81.
54. FDA. Tracleer (bosentan) Prescribing Information. 2018. Available at: www.accessdata.fda.gov/ drugsatfda_docs/label/2017/209279s000lbl.pdf (Date of access: 5th November 2020)
55. Turkish Medicines and Medical Devices Agency. Boselix (Bosentan) Summary of Product Characteristics. Available at: https://titck.gov.tr/ storage/kubKtAttachments/a1d30f7343713.pdf (Date of access: 5th November 2020)
56. Turkish Medicines and Medical Devices Agency. Ventavis (Iloprost) Summary of Product Characteristics. Available at: www.titck.gov. tr/storage/Archive/2019/kubKtAttachments/ K%C3%9CB-UYGUN.pdf_322ff534-5eb1-4ceb-b689- 0de98057453c.pdf (Date of access: 5th November 2020)
57. Turkish Medicines and Medical Devices Agency. Viagra (Sildenafil) Summary of Product Characteristics. Available at: www.titck.gov. tr/storage/Archive/2019/kubKtAttachments/ T%C4%B0TCK%20Onayl%C4%B1%20 K%C3%9CB%20VIAGRA%20100%20MG.pdf_ c1d43e3d-f471-4893-8bcf-7b4ba9d11fea.pdf (Date of access: 5th November 2020)
58. FDA. Revatio (sildenafil) Summary of Product Characteristics, 2014. Available at: www.accessdata.fda.gov/drugsatfda_docs/ label/2014/021845s011,022473s004,0203109s002lbl. pdf (Date of access: 5th November 2020)